Neurology
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global neurology drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
Showing 1–12 of 59 articles
Quick answer
NovaPharmaNews Neurology hub for FDA covers 59 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
FDA Fast Tracks Lundbeck Lu AH69593 for Narcolepsy
FDA Accepts Dyne BLA for z-Rostudirsen in DMD
Hillhurst Bio doses first subject in Phase 2a HBI-002 Parkinson's trial
Neurocrine Biosciences pipeline update: what analysts should watch next
Amgen and Zai Lab Leadership Shifts: Strategic Implications for Pharma BD and Investors
AI and Brain Organoids Combat Parkinson's and Rare Epilepsy
CAPLYTA (Lumateperone) Ranks Highest Among FDA-Approved Adjunctive Depression Treatments in Network Meta-Analysis
InspireMD Receives FDA Approval for SwitchGuard Neuro Protection System CGUARDIANS III Pivotal Trial
Clene's CNM-Au8 Gets FDA Green Light for Accelerated Approval Pathway in ALS Treatment
Novartis Receives Health Canada Approval for Fabhalta Oral Treatment for C3G Patients
Akebia Therapeutics Vadadustat Shows Significant Mortality Reduction in New Kidney Disease Analysis
Spinogenix Tazbentetol Shows Neuroprotective Effects in Glaucoma and Diabetic Retinopathy Preclinical Studies at ARVO 2026
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.